Casuscelli et al. [7] found increased mutation rates in TP53 (58%) and PTEN (24%) as well as imbalanced chromosome duplication (≥ 3 chromosomes, 25%) in chRCC patients with metastatic disease. Here, TP53 is linked to chromophobe renal cell carcinoma.